Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma
NCT06708949Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2025; status: active, not recruiting.
02
Drugs
relatlimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06708949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708949.